Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
Corvus Pharmaceuticals initiated its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa.
Covered in this story
Call it yourself
No calls on $CRVS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Corvus Pharmaceuticals Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.